Titre
Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
St-Amour, P.
Auteure/Auteur
St-Amour, P.
Auteure/Auteur
Joliat, G.R.
Auteure/Auteur
Eckert, A.
Auteure/Auteur
Labgaa, I.
Auteure/Auteur
Roulin, D.
Auteure/Auteur
Demartines, N.
Auteure/Auteur
Melloul, E.
Auteure/Auteur
Liens vers les unités
ISSN
1435-2451
Statut éditorial
Publié
Date de publication
2020-11
Volume
405
Numéro
7
Première page
959
Dernière page/numéro d’article
966
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Multidisciplinary approach with adjuvant chemotherapy is the key element to provide optimal outcomes in pancreas and liver malignancies. However, post-operative complications may increase the interval between surgery and chemotherapy with negative oncologic effects.
The aim of the study was to analyse whether compliance to Enhanced Recovery After Surgery (ERAS) pathway was associated with decreased interval to adjuvant chemotherapy.
Retrospective analysis of all consecutive ERAS patients with surgery for hepatobiliary or pancreatic malignancies at the University Hospital of Lausanne between 2012 and 2016. Multivariate analysis was performed to assess the impact of ERAS compliance on time to chemotherapy.
A total of 133 patients with adjuvant chemotherapy were included (n = 44 liver and n = 89 pancreatic cancer). Median compliance to ERAS was 61% (IQR 55-67) for the study population, and median delay to chemotherapy was 49 days (IQR 39-61). Overall, compliance ≥ 67% to ERAS induced a significant reduction in the interval between surgery and chemotherapy for young patients (< 65 years old) with or without severe comorbidities (reduction of 22 and 10 days, respectively). High compliance in young ASA3 patients with liver colorectal metastases was associated with an increase of 481 days of DFS.
ERAS compliance ≥ 67% tends to be associated with a reduction in the delay to adjuvant chemotherapy for young patients with hepatobiliary and pancreatic malignancies. More prospective studies with strict adhesion to the ERAS protocol are needed to confirm these results.
The aim of the study was to analyse whether compliance to Enhanced Recovery After Surgery (ERAS) pathway was associated with decreased interval to adjuvant chemotherapy.
Retrospective analysis of all consecutive ERAS patients with surgery for hepatobiliary or pancreatic malignancies at the University Hospital of Lausanne between 2012 and 2016. Multivariate analysis was performed to assess the impact of ERAS compliance on time to chemotherapy.
A total of 133 patients with adjuvant chemotherapy were included (n = 44 liver and n = 89 pancreatic cancer). Median compliance to ERAS was 61% (IQR 55-67) for the study population, and median delay to chemotherapy was 49 days (IQR 39-61). Overall, compliance ≥ 67% to ERAS induced a significant reduction in the interval between surgery and chemotherapy for young patients (< 65 years old) with or without severe comorbidities (reduction of 22 and 10 days, respectively). High compliance in young ASA3 patients with liver colorectal metastases was associated with an increase of 481 days of DFS.
ERAS compliance ≥ 67% tends to be associated with a reduction in the delay to adjuvant chemotherapy for young patients with hepatobiliary and pancreatic malignancies. More prospective studies with strict adhesion to the ERAS protocol are needed to confirm these results.
PID Serval
serval:BIB_05CDA588214C
PMID
Open Access
Oui
Date de création
2020-09-18T08:49:15.738Z
Date de création dans IRIS
2025-05-20T17:08:36Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32918147_BIB_05CDA588214C.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
469.17 KB
Format
Adobe PDF
PID Serval
serval:BIB_05CDA588214C.P001
URN
urn:nbn:ch:serval-BIB_05CDA588214C0
Somme de contrôle
(MD5):0f357b27aa1bdb6f7441d8249b4338d5